Background: Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 antibodies. Radiological evaluation of ICB efficacy during therapy is challenging due to tumor immune infiltration. Changes of circulating tumor DNA (ctDNA) levels during therapy could be a promising tool for very accurate monitoring of treatment efficacy, but data are lacking with ICB.
Introduction
Recent clinical results support the use of new immune checkpoint blockers, such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 (e.g. atezolizumab) antibodies, as part of the antitumor armamentarium in several cancer types [1] [2] [3] [4] [5] [6] . Delayed clinical responses have also been observed in some patients, consisting of an initial increase in total tumor size, subsequently followed by tumor shrinkage [2, 3] due to tumor immune infiltration. Unlike chemotherapy, anti-PD-1 or PD-L1 therapy has been shown to provide a benefit in terms of overall survival (OS), but with no improvement of progression-free survival (PFS) in several cancers [1, 2, 5] . These results demonstrate that conventional imaging cannot always reliably predict OS in response to immune checkpoint blockers. It has therefore been proposed that imaging assessment of treatment response or disease progression should be based on two consecutive follow-up imaging studies carried out at least 4 weeks apart, which can prolong the duration of ineffective treatment. Circulating tumor DNA (ctDNA) is a new biomarker that has been mostly investigated as a tool for "liquid biopsy," as it harbors similar mutations to DNA extracted from a "solid" tumor biopsy [7] [8] [9] .
Interestingly, ctDNA detection techniques are quantitative and changes in ctDNA levels during chemotherapy have been associated with tumor response or progression in several tumor types [10] [11] [12] [13] . In five metastatic melanoma patients treated by ipilimumab, ctDNA levels reflected radiological outcomes [14] . In this prospective proof-of-principle study, we investigated whether ctDNA changes are correlated with patient outcome in the specific context of anti-PD-1 therapy.
Materials and methods

Patients and radiological evaluation
The only eligibility criterion for this single-center prospective study was patients treated with pembrolizumab (2 mg/kg every 3 weeks) or nivolumab (3 mg/kg every 2 weeks) as part of the standard care (not in the context of a clinical trial), regardless of their primary histology. All patients included between July 2015 and February 2016 gave their informed consent to participate in the "ALCINA" blood biomarkers study (NCT02866149). After baseline imaging, radiological evaluation was carried out at 8 weeks and repeated 4 weeks later when there was a doubt concerning tumor progression.
Radiological evaluation of efficacy of treatment was carried out by using immune-related response criteria (irRC) [15] , and all patients were followed up until tumor progression.
Plasma sample collection and DNA extraction
Blood samples were drawn from patients included in the study before starting immune therapy (w0) and after 8 weeks of treatment (w8). At each time-point, 10 ml of blood were collected on EDTA tubes at Institut Curie and processed within 1 hour in the circulating cancer biomarkers laboratory, located in the same building. Blood was centrifuged at 820g for 10 minutes. The supernatant was transferred to sterile tubes, centrifuged at 16,000g for 10 minutes and the supernatant was stored at À80 C. Cell-free circulating DNA (cfcDNA) was extracted from 4 mL of plasma using the QIAamp circulating nucleic acid kit (Qiagen), according to the manufacturer's instructions and eluted into 36 ml of buffer. cfcDNA was stored at À20 C and quantified with QuBit fluorometer. The haploid genome equivalent (GE) was calculated assuming a DNA content of 3.3 pg per cell.
ctDNA detection
In this study, ctDNA was detected according to two approaches, depending on whether or not a detectable mutation was already available in the patient's medical records (Figure 1 ). Whenever a mutation was reported in the patient's medical records and deemed detectable by PCR-based assay, this mutation was used as the target to monitor plasma ctDNA: GNAQ and GNA11 point mutations were quantified by bidirectionalpyrophosphorolysis-activated polymerization PCR (Bi-PAP), while point mutations in other genes were assessed by ddPCR (droplet digital PCR) assay. In the absence of any previously determined detectable mutation (i.e. patients with no prior genetic screening of the tumor available in the patient's medical records), cfcDNA samples were directly submitted to targeted next-generation sequencing (NGS). For each patient, the same technique (Bi-PAP, ddPCR or NGS) was applied to the two plasma samples (w0 and w8), with no overlap between techniques.ddPCR probes matching the KRAS, BRAF, and EGFR mutations found in tumor tissue were purchased from Bio-Rad. ddPCR was carried out on a QX100 ddPCR system (Bio-Rad Laboratories). A total volume of 25 ml PCR reaction mixtures was prepared with 12.5 mL 2Â Supermix for probes without dUTP (Bio-Rad), 1.25 ml 20Â target primers/probe, 1.25 mL 20Â wildtype primers/probe, and DNA sample/water (variable volume). A median of 13 ng (range, 10-14 ng ) of DNA were analyzed for each plasma sample. The PCR reaction was partitioned into a mean of 14 000 droplets per sample using the QX100 Droplet Generator (Bio-Rad) according to the manufacturer's instructions. Samples were then transferred to a Bio-Rad QX-100 droplet reader and analyzed on the basis of fluorescence intensity by QuantaSoft v1.4.0.99 software from Bio-Rad. Each test contained at least two negative control wells with no DNA and wild-type DNA. The mutant DNA and wild-type DNA concentrations were estimated by the Poisson distribution. Mutant allele frequency (MAF) was calculated as follows: MAF (%) ¼ [mutant copy/(wild-type þ mutant copy)] Â 100.
Bi-PAP assays, previously set up in our laboratory for detection of GNAQ/GNA11 mutations in plasma with excellent sensitivity and specificity [16] , were carried out on 10 ml DNA in three independent experiments. The PCR reaction was carried out in a total volume of 25 ml including DNA sample, 1 U KlenTaq S (Scientech Corp, MO), 1Â KlenTaq S buffer, 8% (v/v) dimethyl sulfoxide, 25 mM of each dNTP, 1 mM dithiothreitol (DTT), 0.1Â ROX calibration dye, 0.2Â SYBR Green I dye (Life Technologies) and optimized concentrations of primers, as described previously. All PCR-based assays used for ctDNA detection (bi-PAP or ddPCR) had been validated previously (sensitivity >0.1% mutant DNA diluted in normal DNA) [16, 17] .
Targeted-NGS was carried out on a panel of 39 cancer related-genes (supplementary Table S1 , available at Annals of Oncology online). Following multiplex PCR amplifications and library preparation, samples were subjected to ultra-deep sequencing (average coverage around Â12 000) on Illumina HiSeq2500 instrument. Methods are available in supplementary material S1, available at Annals of Oncology online. For samples directly submitted to massively parallel sequencing, ctDNA level, expressed in hGE/mL of plasma, was calculated by multiplying the level of cell-free circulating DNA measured by the percentage of mutant allele fraction measured by sequencing.
Statistical analysis
PFS and OS were defined as the time elapsed between the date of inclusion and the date of disease progression or death from any cause, or the date of death, respectively. Characteristics for each group were compared using chi-square or Fischer's exact test for categorical variables. The median point estimate and 95% CI for PFS and OS were estimated by the Kaplan-Meier method. Survival curves were compared by using an unstratified log-rank test. 
Results
Patient characteristics and ctDNA detection
Plasma samples were prospectively collected at w0 and w8 in 15 patients, 10 of whom were treated for metastatic non-small cell lung cancer, 3 for metastatic uveal melanoma, and 2 for metastatic microsatellite-instable colorectal cancer (Table 1, Figure 1 ). Median follow-up was 10.8 months (range, 3.2-16.3 months), and median duration of treatment was 4.7 months [range, 1->16 (ongoing)]. Patients were treated by nivolumab, except for two patients with colorectal cancer, who were treated by pembrolizumab. Ten patients discontinued anti-PD-1 therapy due to disease progression, two due to putative undocumented toxicity (asthenia and myalgia in one patient; pneumonitis in one patient), and three patients were still on treatment at the time of data analysis. Median cfcDNA was 3121 haploid genome equivalents (range, 364-54 242), and ctDNA was detected at baseline (w0) in 10/15 patients (67%) ( Table 1 ). The median mutant allele frequency in these 10 patients was 3.0% (range, 0.24%-39.1%) and the median ctDNA level was 200 copies/ml of plasma (range, 0.5-3808). ctDNA remained undetectable at w8 in all five patients with undetectable ctDNA levels at w0. No significant association was observed between ctDNA levels at w0 and age, sex, performance status, cancer type, number of metastatic sites, or number of previous lines of systemic therapies.
ctDNA level changes and tumor response
Relative changes of tumor size between w0 and w8 (irRC) were compared with synchronous changes in ctDNA levels: a global statistically significant association was observed between the two variables ( Figure 2 , Spearman correlation r ¼ 0.86, P ¼ 0.002). Strikingly, patients with complete clearance of ctDNA at w8 (i.e. undetectable ctDNA at w8; N ¼ 2 patients) displayed a synchronous radiological response, while the other eight patients (with a limited decrease or an increase of ctDNA levels) had stable or progressive disease. One patient, in whom plasma DNA was analyzed by NGS, presented three distinct mutations at baseline. At w8, complete clearance was observed for PTPN11 and KEAP1 mutations, while the TP53 mutation remained detectable. This patient presented disease progression according to irRC, but one of the target lesions (adrenal metastasis) displayed marked shrinkage during anti-PD1 therapy, suggesting that different tumor subclones may respond in different ways.
Changes in ctDNA status and patient outcome Figure 3 shows the changes in tumor size over time for each of the 15 patients included in this study according to their ctDNA status: detectable at w8 and persistently detectable at w8, undetectable at both w0 and w8; detectable at w0 and undetectable at w8. Five irRC responses were observed, exclusively in patients with undetectable ctDNA at w8. Patients with undetectable ctDNA at w8 had a significantly better PFS than patients with persistently detectable ctDNA [ Figure 4A ; hazard ratio (HR) ¼10.2; 95% CI 2.5-41; median 11 versus 2 months, P ¼ 0.001], and OS ( Figure  4B , HR ¼ 15, 95% CI 2.5-95, P ¼ 0.004). Similar results were obtained using RECIST criteria (not shown). ctDNA detection at w0 was not associated with PFS (detectable versus undetectable: HR ¼ 1.9, 95% CI 0.58-6.1, P ¼ 0.29) but was associated with OS: OS was improved in patients with undetectable ctDNA at w0 (HR ¼ 6.8, 95% CI 1. 
Discussion
This proof-of-principle study demonstrates that serial analysis of plasma-derived ctDNA is correlated with early tumor response to Unless otherwise specified, anti-PD1 therapy was discontinued at tumor progression. : N ¼ 2 patients in whom anti-PD1 therapy was discontinued because of toxicity; one of these patients experienced a sustained response to therapy. ᭡: N ¼ 3 patients with no progression at the time of analysis.
anti-PD-1 therapy and patient outcomes. As inefficient PD-1 blockade could possibly be deleterious, ctDNA monitoring could play a critical role in treatment decisions, especially when the synchronous radiological evaluation is difficult or equivocal.
In this small cohort, we observed the detrimental impact of ctDNA detection at baseline on OS, which has been reported in previous studies [18] . As demonstrated previously, the fraction of patients with detectable levels of ctDNA is correlated with tumor burden [19] and proliferation [12] , two well-known prognostic factors. Notwithstanding this long-term prognostic impact, ctDNA detection at baseline is not a predictive factor of response to therapy: in this cohort, two patients with ctDNA detected at w0 and undetectable at w8 had extremely good tumor response and outcomes. Other patients with ctDNA undetectable at both timepoints also had prolonged PFS. Our results therefore suggest that only patients with ctDNA levels below the limit of sensitivity of ctDNA detection techniques at w8 benefit from anti-PD-1 therapy. Similar results have recently been reported with standard chemotherapy in metastatic non-small cell lung cancer [20] . Early changes in ctDNA levels therefore reflect response to ICB, similar to the results reported for other types of antitumor therapy, such as chemotherapy [10] [11] [12] [13] 20] or targeted therapy [21] .
Several mutations in circulating cell-free DNA were detected by NGS at baseline in two patients. After 2 months of anti-PD-1 therapy, all initially detected mutations were situated below the limit of detection for one patient (who displayed a sustained tumor response). In the second patient, one mutation remained detectable at w8, while the other two mutations had become undetectable. This patient presented a dissociated tumor response and poorer outcome, suggesting that monitoring several mutations, when they are detectable at baseline, could be more informative and may reflect the clonal heterogeneity of response to anti-PD-1 therapy.
To complement this proof-of-concept study, confirmatory observational cohorts are needed to define the ctDNA cut-offs to be used as a real-time "companion" biomarker and the medical and economic benefits of this type of monitoring. Earlier time-points for ctDNA monitoring (e.g. 4 weeks after initiation of therapy) could also be investigated, allowing early selection of patients likely to benefit from ICB therapy.
In summary, our prospective cohort suggests that ctDNA level monitoring at baseline and at 2 months is a valuable tool to assess tumor response and predict outcome in patients treated with anti-PD-1 therapy, but these results need to be validated in a larger and more homogeneous study. 
